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all the assessed clinical parameters at the sites of sample 
collection except for bleeding on probing. The level of 
HNP1-3 per measure point showed a statistically signifi-
cant increase (baseline—3 months: p = 0.05, baseline—6 
months: p = 0.007). Within the limits of the study, it can be 
stated that nonsurgical periodontal therapy with additional 
systemic administration of Amoxicillin and Metronidazole 
increases the level of HNP1-3 in GCF.
Keywords Chronic periodontitis · Gingival crevicular 
fluid · Alpha-defensins · Human neutrophil peptide
Introduction
Chronic periodontitis is an infectious disease characterized 
by inflammatory destruction of the tooth supporting tis-
sues. The disease severity depends on the dynamic balance 
between dental plaque bacteria, genetic factors that condi-
tion the innate immunity of the host to bacterial infection, 
and environmental factors (Nishihara and Koseki 2004; 
Socransky and Haffajee 2005).
The oral cavity is a complex microbial environment 
inhabited by approximately 700 different bacterial species 
(Haffajee and Socransky 2006; Kolenbrander et  al. 2006; 
Paster et al. 2006). Some of these microorganisms consti-
tute the commensal flora; others are potentially pathogenic. 
This rich bacterial flora is controlled by innate immune 
responses of oral epithelial cells, saliva, and gingival cre-
vicular fluid (GCF). In addition, proteins and antibacte-
rial peptides (AMPs) are involved in this local defen-
sive mechanism and maintain the balance between oral 
health and disease (Dale and Frederics 2005; Kinane et al. 
2007). Human saliva and GCF contain at least 45 various 
AMPs, which belong to functionally different classes and 
Abstract The rich bacterial flora of oral cavity is con-
trolled by innate immune response, including antibacterial 
peptides and among them human neutrophil peptides 1–3 
(HNP1-3). The knowledge of the involvement of HNPs in 
innate and acquired immunity of the periodontium is frag-
mentary. The aim of the study was to assess alterations in 
HNP1-3 levels in the gingival crevicular fluid (GCF) of 
chronic periodontitis patients before and after nonsurgi-
cal periodontal therapy. Nineteen patients with chronic 
periodontitis were qualified to the study. After periodontal 
examination, one site with pocket depth (PD) ≥4 mm was 
selected. All the patients received periodontal treatment 
involving scaling and root planing with additional sys-
temic antibiotic therapy (Amoxicillin 375  mg three times 
daily and Metronidazole 250  mg three times daily for 7 
days). Prior to therapy, 3 and 6 months after it, clinical 
periodontal parameters were measured and GCF was col-
lected from previously chosen site. The level of HNP1-3 in 
GCF was determined by means of a commercially available 
enzyme-linked immunoassay kit. The periodontal therapy 
caused a statistically significant (p < 0.001) decrease in 
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structurally contain small cationic peptides, enzymes, and 
large agglutinating proteins. This functional and structural 
diversity seems to be indispensable to protect oral epithe-
lial cells against a large number of potentially pathogenic 
microbes and to maintain homeostasis between commen-
sals and pathogens. The functional group of cationic pep-
tides consists of adrenomedullin, α-defensins (HNP: human 
neutrophil peptides), β-defensins, cathelicidin, histatins 
1 and 3, statherin, CCL28, azurocidin, calcitonin gene-
related peptide neuropeptides, neuropeptide Y, substance P, 
and vasoactive intestinal peptide (Gorr and Abdolhosseini 
2011). In this group, defensins are the best characterized 
antibacterial molecules found in humans; however, their 
role in immune mechanisms has not been fully explained 
yet.
Alpha-defensins (HNP1-4) are located in the azurophilic 
granules of neutrophils, whereas HNP5-6 are present in 
the intestinal Paneth’s cells (Doss et al. 2010; Lundy et al. 
2005). In oral environment, α-defensins are present in the 
salivary glands and saliva as well as in GCF (Brogden 
et al. 2003). They can be found in oral epithelium, crevicu-
lar/pocket epithelium, and junctional epithelium, which is 
associated with polymorphonuclear leukocytes migration. 
α-defensins present in junctional epithelium always occur 
in close connection with neutrophils that migrate through 
the tissue even in the state of health. Likewise, α-defensins 
are found in subepithelial connective tissue (Dale et  al. 
2001; Dale and Frederics 2005).
Defensins, which are involved in the innate immunity of 
the host, are able to kill Gram(+) bacteria, Gram(−) bac-
teria, fungi, and some viruses (Komatsuzawa et  al. 2007; 
Miyasaki et al. 1990). In addition, they are classified as ele-
ments linking innate and acquired immunity, through che-
moattraction of  CD4+ T cells and immature dendritic cells 
to the sites of infection. They can also stimulate degranu-
lation of mastocytes, regulate activation of the comple-
ment, and increase phagocytosis of macrophages (Biragyn 
2005; Dale and Frederics 2005; Komatsuzawa et al. 2007; 
McCormick and Weinberg 2010; Otvos 2005).
As shown by animal models, AMPs have a key role in 
the prevention and eradication of infections (Bowdish et al. 
2005; Otvos 2005). However, their role in human immunity 
has not been fully elucidated. There is growing evidence on 
the immunomodulatory properties of antibacterial peptides, 
including HNP1-3. The knowledge of the involvement of 
HNPs in innate and acquired immunity of the periodontium 
is fragmentary and requires further studies.
The study objective was to assess alterations in HNP1-3 
levels in the GCF of chronic periodontitis patients after 
nonsurgical periodontal therapy. Until now, very few arti-
cles have been published on the presence of GCF HNP1-3 
in healthy subjects and in patients with chronic periodon-
titis (Lundy et al. 2005; Puklo et al. 2008; Türkoğlu et al. 
2010). Besides, to our knowledge, human neutrophil pep-
tides have never been investigated after periodontal ther-
apy. Therefore, there is lack of studies evaluating the effects 
of nonsurgical periodontal therapy on the HNP1-3 levels.
Materials and Methods
Patients
Nineteen patients (14 women and 5 men, mean age: 50.58) 
with chronic periodontitis were included in the study. The 
exclusion criteria were: severe systemic disease that might 
affect periodontal therapy (patients with controlled diabetes 
mellitus were also excluded), pregnancy, and breastfeeding, 
systemic antibiotic therapy 12 months prior to treatment, 
allergy to metronidazole and/or penicillin. Inclusion crite-
ria were as follows: moderately advanced chronic periodon-
titis (Armitage 1999), the presence of at least one tooth in 
the quadrant, and the overall number of teeth at least 12. 
No smokers were included. All the patients were informed 
about the study and provided their written consent. The 
study was approved by the Ethics Committee, Medical Uni-
versity of Bialystok, and conducted according to the princi-
ples outlined in the Declaration of Helsinki on experimen-
tation involving human subjects.
Clinical Parameters
Prior to therapy (baseline), as well as 3 and 6 months after 
it, each patient underwent periodontal examination with 
the same type of periodontal probe UNC 15 (Hu-Friedy 
Co., Chicago, IL, USA) to determine probing pocket 
depth (PD), gingival recession (GR), plaque index (PI), 
and bleeding on probing (BOP). Clinical attachment level 
(CAL) was calculated by adding PD to GR. The examina-
tion was performed by one masked and calibrated investi-
gator (AS). At baseline, the clinician chose one periodon-
tal pocket (≥4  mm deep) to collect GCF for biochemical 
analyses. The tooth that was chosen for GCF collection was 
probed in six points: mesiovestibular, midvestibular, dis-
tovestibular, mesiolingual, midlingual, and distolingual to 
determine PD, GR, and CAL. BOP was measured in four 
measure points (mesiovestibular, midvestibular, distovestib-
ular, and midlinual) according to Ainamo and Bay (1975). 
PI was determined in four tooth surfaces (mesiovestibular, 
midvestibular, distovestibular, and midlingual) according to 
Silness and Löe (1964).
GCF Sampling
At baseline as well as 3 and 6 months post-therapy, GCF 
was collected from the periodontal pocket (≥4 mm depth) 
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chosen on the first visit and sulcus fluid flow rate (SFFR) 
was determined in relative periotron units (PU). The tooth 
was isolated with cotton rolls, dental plaque was removed 
gently, and the tooth was air dried. GCF was collected 
using paper strips (Periopaper, Interstate Drug Exchange, 
Amityville, NY, USA), which were placed in the periodon-
tal pocket at 1–2 mm depth for 30  s. The blood-contami-
nated strips were discarded. The GCF volume absorbed on 
a paper strip was measured using a calibrated device (Peri-
otron 8000, Oraflow, Plainview, NY, USA). After meas-
urement, the samples were immediately placed in Eppen-
dorf tubes containing 20 μl phosphate buffered saline and 
frozen.
Periodontal Therapy
Following one or more appointments, including thorough 
oral hygiene instructions and supragingival scaling and 
polishing, all pockets ≥4  mm were treated by means of 
SRP using ultrasonic scalers (LM-Instruments, Parainen, 
Finland) and hand instruments (Hu-Friedy, Chicago, IL, 
USA) by one trained clinician (ED). Oral hygiene instruc-
tions were as follows: to brush teeth twice daily using roll 
technique and at least once a day to use dental floss or/and 
interdental brushes.
After SRP, the patient was prescribed systemic antibiotic 
therapy as follows: Amoxicillin 375  mg three times daily 
and Metronidazole 250 mg three times daily for 7 days (van 
Winkelhoff et al. 1989).
GCF HNP1-3 Analysis
The concentration of HNP1-3 in GCF was determined with 
the use of commercially available enzyme-linked immuno-
assay (ELISA) kit (Human HNP1-3, Hycult Biotechnology, 
Uden, The Netherlands) following the producer’s instruc-
tion. The minimum detectable amount of HNP1-3 was 
0.156  ng/ml. The result was expressed as the amount per 
measure point (ng/site).
Statistical Analysis
The statistical analysis was performed with the use of Sta-
tistica 8.0, StatSoft for Windows  (SPSS®, Chicago, IL, 
USA). Distribution normality was analyzed using the Kol-
mogorov–Smirnov test with the Lilliefors correction and by 
the Shapiro–Wilk test. Normal distribution of the quantita-
tive variables was not found. The Friedman’s ANOVA test 
with post-hoc Conover’s test was used to compare three 
dependent variables (changes in the parameters in time). 
Correlations between qualitative features (BOP point) were 
checked using the Chi-square test of independence.
Spearman’s rank order correlation coefficient was also 
determined to analyze correlations between the amount of 
HNP1-3 per measure point and clinical parameters and sul-
cus fluid flow rate.
Statistical differences were considered significant at 
p ≤ 0.05. The estimated power of the test was 0.8051.
Results
The study group included 19 subjects with chronic peri-
odontitis. Table  1 shows clinical periodontal parameters 
(PD, CAL, PI, BOP, and SFFR) at the site of collection 
for laboratory analysis at baseline, and 3 and 6 months 
post-therapy. The periodontal therapy has led to statisti-
cally significant improvement of most of the evaluated 
clinical parameters at the sites of sample collection (PD, 
CAL, PI, SFFR: p < 0.001). The only exception was the 
change in BOP where the reduction did not reach statistical 
significance.
The level of HNP1-3 per measure point increased sta-
tistically significant after treatment. There was statisti-
cal difference between baseline and 3 months (p = 0.05) 
and baseline and 6 months (p = 0.007). Figure  1 shows 
HNP1-3 at baseline, as well as 3 and 6 months after ther-
apy. Figure 2 presents a statistically significant decrease 
Table 1  Clinical periodontal 
data of sampling site
ME median, Q1 lower quartile, Q3 upper quartile, PD pocket depth, CAL clinical attachment level, PI 
plaque index, SFFR sulcus fluid flow rate, BOP bleeding on probing
*The Anova Friedman’s test with Kendall’s correlation of consistency
† The Pearson’s Chi-square test
Periodontal parameter Baseline 3 months 6 months p
Sampling sites ME (Q1–Q3)
 PD (mm) 7 (6–8) 4 (3–6) 4 (3–5) <0.001*
 CAL (mm) 7 (6–9) 6 (3–7) 5 (4–6) <0.001*
 PI 3 (1–3) 1 (0–1) 0 (0–1) <0.001*
 SFFR (PU) 141 (107–177) 80 (61–125) 88 (52–131) <0.001*
 BOP(+) 12 6 6 0.075†
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in SFFR, i.e., gingival fluid volume expressed in rela-
tive PU (baseline—3 months: p < 0.001 and baseline—6 
months: p < 0.001).
Correlations between HNP1-3, SFFR, and PD and CAL 
were checked. Only after 6 months, a strong positive cor-
relation was observed between CAL and SFFR (R = 0.519) 
and an average positive correlation between PD and SFFR 
(R = 0.462). Additional analysis of Spearman’s rank corre-
lations showed average negative correlation (R = −0.473) 
between the level of HNP1-3 expressed as ng/measure 
point and CAL.
Discussion
The effective response of the host to bacterial infection is 
initially mediated by neutrophils via their migration to the 
inflammatory zone, also to GCF. Neutrophils constitute the 
main link of human body defense and are able to kill micro-
organisms using oxygen-dependent and oxygen-independ-
ent mechanisms (Dennison and van Dyke 1997; Nussbaum 
and Shapira 2011). The latter involves α-defensins, associ-
ated with nonspecific defense, which account for 30–50% 
of azurophilic granules, i.e., 5–7% of total protein content 
in neutrophils. The bactericidal action of HNPs is associ-
ated with the formation of canals in the cell membranes 
and a change in their semipermeability in bacteria (Miya-
saki et al. 1990; Otvos 2005). This action is nonspecific and 
can lead to the destruction of own cells, especially at high 
concentrations, which is part of tissue destruction mecha-
nism mediated by neutrophils (Bowdish et al. 2005; Puklo 
et  al. 2008). HNP1 was proven to stimulate keratinocytes 
proliferation, attachment, and spreading, whereas higher 
doses increased the bacterial attachment and keratinocyte 
death (Gursoy et al. 2013).
The sensitivity of Gram-negative bacteria to AMPs is 
mainly investigated on periopathogens and is species- or 
even strain-dependent. In  vitro studies have shown sensi-
tivity of Capnocytophaga sputigena and Capnocytophaga 
gingivalis to the actions of HNP1 and HNP2 as well as 
Capnocytophaga ochracea to HNPs 1, 2, 3. E. corrodens 
and A. actinomycetemcomitans were resistant to HNP 
at a concentration of 500  μg/ml (Miyasaki et  al. 1990), 
whereas P. intermedia to HNP1, HNP2, and HNP3. HNP1 
and HNP2 had only minor effects on T. forsythia (Lee 
et al. 2010). These studies show that α-defensins are rela-
tively slightly effective against periopathogens. It can be 
explained by bacterial defense mechanisms against HNPs. 
An example can be Fusobacterium nucleatum that is 
able to inhibit membrane permeability and increase bio-
film and planktonic growth against HNP1 (Keskin et  al. 
2014). Despite low direct activity against periopathogens, 
α-defensins are believed to have immunomodulatory prop-
erties (Biragyn 2005; Bowdish et al. 2005). In addition, at 
high concentrations, they are cytotoxic against tumor and 
eukaryotic cells. Positively charged HNP1 is suggested to 
interact with negatively charged surface molecules and pro-
mote the permeability of lipid membranes (Peschel 2002). 
DNA injury and lysing tumor cells are other mechanisms of 
action against tumors (Gera and Lichtenstein 1991). Recent 
study by Musrati et  al. (2016) demonstrated that HNP1 
suppresses the secretion of MMP-2, -8, -9 in oral squamous 
cell carcinoma cells. It has both protumorigenic (suppress-
ing MMP-8, which is associated with less cancerous inva-
sion) and protecting action (MMP-2 and -9 are involved in 
carcinogenesis) (Musrati et al. 2016).
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Fig. 1  Level of HNP1-3 in gingival crevicular fluid obtained from 
chronic periodontitis patients before treatment, 3 and 6 months after 
therapy. The results present median, and 25th and 75th percentiles. 




























Fig. 2  GCF volume (in relative periotron units) obtained from peri-
odontal pockets of chronic periodontitis patients before treatment, 3 
and 6 months after therapy. The results present median, and 25th and 
75th percentiles. NS non significant, p p value-Friedman’s ANOVA 
test with post-hoc Conover’s test
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Bacterial infections enhance the expression of 
α-defensins (increased amount in body fluids in patients 
with inflammations and infections) (Fang et  al. 2003; 
Ihi et  al. 1997), also in the saliva of subjects with oral 
inflammations (Mizukawa et  al. 1999). HNP1-3 are pre-
sent constitutively in peripheral blood neutrophils. Fang 
et  al. (2003) showed that they were neither up-regulated 
nor down-regulated by lipopolisaccharide or heat-killed P. 
aeruginosa.
Our results showed the level of HNP1-3 in GCF of 
patients with chronic periodontitis before, 3 and 6 months 
after nonsurgical periodontal therapy. Interestingly, its 
amount increased after effective periodontal therapy. The 
rise in the level of HNP1-3 was not related to the enlarged 
volume of GCF at the site of its collection, since the therapy 
caused resolution of inflammation, which was manifested 
by a decrease in SFFR. Other authors who did research 
on HNP1-3, such as Ihi et al. (1997), noted an increase of 
these molecules during infection, which after elimination 
of inflammation factor by the therapy decreased to the level 
close to that observed in healthy controls. Ihi et al. (1997) 
compared samples of plasma, blood, and other body fluids 
in healthy subjects and patients with three types of infec-
tion. The levels of HNP1-3 in patients with bacterial infec-
tion, nonbacterial infection, and pulmonary tuberculosis 
were, respectively, 4.2, 3.2, and 1.8 times higher compared 
to the mean control values. They also showed that elevated 
values of HNP at the time of the infection onset returned 
to normal after treatment and were comparable with those 
in the healthy group. Similar results have been reported by 
Isomoto et al. (2004) who examined the levels of HNP1-3 
in healthy subjects and patients with diagnosed Helicobac-
ter pylori infection. The levels of HNP1-3 in gastric juice 
of patients with H. pylori infection were statistically sig-
nificantly higher than in healthy subjects but dropped after 
treatment. Patients with active tuberculosis had higher lev-
els of α-defensins in plasma and BAL fluid samples than 
healthy controls (Ashitani et al. 2002).
The increase of HNP1-3 level following periodontal 
therapy can be associated with specific biology of the gin-
gival crevice, which, even in the state of health, contains 
neutrophils migrating from tissues in response to bacte-
rial flora. This has been confirmed by histological studies 
which demonstrate that the gingival connective tissue free 
of inflammatory cells probably does not exist (Griffiths 
2003). However, it should be noticed that sterile status 
in the gingival crevice is impossible and even unneces-
sary to achieve. The effective immune system of the host 
shows appropriate response to the bacteria that survived 
the therapy (Ishikawa and Baehni 2004). Another cause of 
the elevated levels of α-defensins after periodontal therapy 
can be elimination of periopathogens. Defensins act as 
substrates for certain bacterial proteinases, e.g., produced 
by P. gingivalis (Puklo et al. 2008; Mailhot et al. 1998). P. 
gingivalis is capable of proteolytic decomposition of many 
AMPs and lower levels of HNP1-3 before therapy can be 
due to their proteolytic degradation (Puklo et  al. 2008). 
Periodontal therapy using systemic antibiotic therapy with 
amoxicillin and metronidazole reduces statistically the 
number of red complex bacteria, including P. gingivalis 
(Silva et al. 2011) and the number of patients harboring P. 
gingivalis (Winkel et al. 2001). On the other hand, antimi-
crobial peptides can aggregate. The higher the concentra-
tion of peptides, the bigger is the aggregation. That may 
influence the sensitivity of the ELISA tests (Güncü et  al. 
2015). Such a test was used in our study. It can be assumed 
that before treatment, high concentration of HNP1-3 was 
not effectively measured by ELISA method because of 
HNPs aggregation. The other reason can be binding of anti-
microbial peptides to the bacterial lipopolysaccharides and 
DNA. It may make defensins to stay in the pellet after the 
initial centrifugation of the sample (Güncü et al. 2015).
The relationship between enlarged volume of GCF and 
increased severity of inflammation has been well docu-
mented (Armitage 2004; Griffiths 2003). It is also sug-
gested that the increased GCF flow rate together with a 
growing tendency to bleed is one of the earliest symptoms 
of gingivitis. The increased GCF volume may indicate an 
ongoing subclinical inflammatory process. Even the sites 
classified as clinically healthy may differ in the degree of 
subclinical inflammation. This is confirmed by histological 
investigations showing that the gingival connective tissue 
free of inflammatory cells may not exist. The GCF volume 
and its flow rate are used as indices for changes in vascu-
lar permeability at an early stage of inflammation (Griffiths 
2003).
In our study, all GCF samples were collected over the 
same period of time and data were presented as the total 
amount per measure point. This resulted from an assump-
tion that with active inflammation, an increase in fluid 
volume could give a false reading of the dilution values of 
the studied molecule (only locally present) or its elevated 
concentration when it is simultaneously expressed in the 
peripheral blood (Griffiths 2003). Other authors also sug-
gest higher reliability of results expressed as the amount 
per measure point rather than concentration (Lamster et al. 
1986; Lamster and Ahlo 2007; Türkoğlu et al. 2010).
We assessed HNP1-3 after nonsurgical periodontal 
therapy; since to our knowledge, such assessments had 
never been undertaken before and researchers focused 
mainly on their presence in healthy or diseased periodon-
tium (Lundy et al. 2005; McKay et al. 1999; Puklo et al. 
2008; Rangé et al. 2012; Türkoğlu et al. 2010). A study 
conducted by Lundy et  al. (2005) proved higher levels 
of HNP1-3 in GCF in healthy sites (without statistical 
significance), which they associated with intact defensin 
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barrier in the state of health. Similar observations have 
been reported by Türkoğlu et  al. (2010), who showed 
higher levels of HNP1-3 in GCF in healthy subjects than 
in patients with gingivitis, aggressive periodontitis, and 
chronic periodontitis. However, all the study groups had 
similar amounts of HNP1-3 expressed in ng/site. Puklo 
et  al. (2008) demonstrated different results showing that 
the level of HNP1-3 was the highest in patients with 
chronic periodontitis, high in those with aggressive peri-
odontitis, and the lowest in healthy subjects.
In our study, nonsurgical periodontal therapy con-
sisted of scaling and root planning with additional use of 
antibiotics. Systemic antibiotic therapy may also influ-
ence HNP1-3 levels in GCF. The effect of unassisted 
periodontal debridement on HNP1-3 levels in GCF is still 
unknown and needs further studies.
Our first aim was to indicate the level of HNP1-3 in 
GCF before and after treatment. HNPs are rarely exam-
ined in GCF, and none of the previous work used the 
same ELISA kit we did. The second problem is the 
number of patients that could be included in the study, 
because there is small number of volunteers fulfilling 
inclusion criteria. That is why we did not perform pri-
mary power analysis, what is a weak point of this study. 
However, we did it post hoc. The estimated power was 
0.8051.
Limitations of the conventional periodontal therapy 
seem to stimulate a search for novel and better forms of 
treatment. A tempting option is to find a component of 
innate immunity that would effectively combat periodontal 
pathogen bacteria without exerting toxic effects on the host 
cells. Perhaps, antibacterial peptides may play such a role. 
Immunomodulatory therapy could be most successful with 
mechanical debridement. The prevention and treatment of 
periodontitis may depend upon immunomodulatory, anti-
bacterial, and anti-inflammatory properties of AMPs. How-
ever, the knowledge of their action is still too limited and 
none of the hundreds of AMPs so far discovered have clini-
cal implications in periodontal treatment.
In conclusions, based on the above data, within the 
limits of the study, it can be stated that overall amount of 
HNP1-3 increases in GCF of chronic periodontitis patients 
after nonsurgical periodontal therapy using systemic 
administration of Amoxicillin and Metronidazol. Further 
studies are needed to fully elucidate the role of HNP1-3 in 
periodontal disease.
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